Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AGLTS:0VRQ -0.35%46 Debt-to-Equity is 0.45 as of Jun. 2026, which is 309% above its 10-year median of 0.11. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 968 Biotechnology companies, CRISPR Therapeutics AG ranks worse than 72.52% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CRISPR Therapeutics AG's Debt-to-Equity or its related term are showing as below:
LTS:0VRQ'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.11 Max: 0.45
Current: 0.45
During the past 12 years, the highest Debt-to-Equity Ratio of CRISPR Therapeutics AG was 0.45. The lowest was 0.03. And the median was 0.11.
LTS:0VRQ's Debt-to-Equity is ranked worse than 72.52% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0VRQ: 0.45
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CRISPR Therapeutics AG Debt-to-Equity Related Terms
CRISPR Therapeutics AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs MANE, EWTX, CAI: Debt-to-Equity Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a Debt-to-Equity of 0.45 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CRISPR Therapeutics AG and its competitors. This is 309% above median its historical median of 0.11. Over the past decade, CRISPR Therapeutics AG's Debt-to-Equity has ranged from 0.03 to 0.45. According to the industry distribution chart, CRISPR Therapeutics AG ranks #702 out of 968 companies in the Biotechnology industry, placing it in the top 72.5%.
Is CRISPR Therapeutics AG's Debt-to-Equity too high?
CRISPR Therapeutics AG's current Debt-to-Equity of 0.45 is 309% above median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.45. The Biotechnology industry median Debt-to-Equity is 0.16. CRISPR Therapeutics AG's value of 0.45 is 181.3% above this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #702 out of 968 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Debt-to-Equity compare to MANE and EWTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #702 out of 968 companies for Debt-to-Equity. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Debt-to-Equity is 0.16. CRISPR Therapeutics AG's value of 0.45 is 181.3% above this benchmark. Historically, CRISPR Therapeutics AG's own Debt-to-Equity has ranged from 0.03 to 0.45 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 0.16, CRISPR Therapeutics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Debt-to-Equity of 0.45 is 181.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Debt-to-Equity is 0.45, which is 309% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The current Debt-to-Equity is 0.45, which is 309% above median its 10-year median of 0.11 and 181.3% above the Biotechnology industry median of 0.16. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Debt-to-Equity is 0.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score
Get the complete analysis for LTS:0VRQ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
